← All trials
NCT05037500
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Nov 15, 2024
- Completion date
- Nov 15, 2025
- First posted
- Sep 8, 2021
- Last posted
- Oct 29, 2021
- Enrollment
- 19
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- State University of New York, BuffaloLead sponsor
- State University of New York, BuffaloOverall official - principal investigator
- National Comprehensive Cancer NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.